Breaking News Headlines Today

News from CureDuchenne

Stay current with all the latest and breaking news from CureDuchenne. Compare headlines and media bias behind news outlets on stories breaking today.

In total, 15 have been published by CureDuchenne which Ground News has aggregated in the past 3 months.

Ground News rates CureDuchenne’s media bias as unknown. Ground News is unable to assign a bias rating and does not have ratings available from Ad Fontes Media, All Sides, and Media Bias/Fact Check.

We’ve assigned a rating of Unknown factuality to CureDuchenne. You can read more about how we’ve determined CureDuchenne’s credibility and reliability as a news source here: https://groundnews.lakegeneva.lib.wi.us/rating-system.

Information about CureDuchenne

Where is CureDuchenne located?CureDuchenne's Website

Media Bias Ratings

Do you diasgree?

Edit bias

Learn more about Media Bias Ratings.

Factuality

Learn more about Factuality Ratings

Reveal Factuality Ratings by upgrading to a Premium account.

Tap Upgrade to explore subscription options to meet all your reading needs.

Ownership

Learn more about Ownership categories

Reveal Ownership Data by upgrading to a Vantage account.

Tap Upgrade to explore subscription options to meet all your reading needs.

Top CureDuchenne News

United States · United States

Sarepta : Restructuring and Elenidys - Strategic Plan

Sarepta: Restructuring and Elenidys – Strategic Plan Sarepta Therapeutics: Restructuring Massive after Deborations in Genic Therapy – Urgent News The pharmaceutical company Sarepta... The post Sarepta: Restructuring and Elenidys – Strategic Plan appeared first on World News.See the Story

Brogidirsen and the Promise of Exon 44 Skipping: New Horizons in RNA Therapy for Duchenne Muscular Dystrophy – Patient Worthy

Duchenne muscular dystrophy (DMD) is a devastating, inherited muscle-wasting disorder caused by mutations in the DMD gene, leading to an absence of functional dystrophin protein. While current standards of care, such as corticosteroids and supportive therapies, have extended patient lifespans and improved quality of life, they remain largely palliative and do not address the root […]See the Story

Sarepta Provides Safety Update for ELEVIDYS and Initiates Steps to Strengthen Safety in Non-Ambulatory Individuals with Duchenne

60% Center coverage: 5 sources

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jun 15, 2025-Artificial Intelligence See the Story

FDA Meeting Gives Window Into Gene Therapy Field’s Angst

100% Center coverage: 2 sources

Gene therapy experts and advocates warning of the sector’s many challenges found a receptive audience in FDA leadership at a regulatory forum Thursday.FDA · United States See the Story

REGENXBIO REPORTS NEW POSITIVE FUNCTIONAL DATA FROM PHASE I/II AFFINITY DUCHENNE® TRIAL OF RGX-202

100% Left coverage: 1 sources

RGX-202 demonstrating consistent evidence of positively changing disease trajectory for DuchenneAll dose level 2 participants exceeded external natural history controls on all functional measuresBiomarker data demonstrate consistent, robust microdystrophin expression and transduction levels across all treated agesOne new participant aged…See the Story

PepGen to discontinue development of experimental Duchenne therapy; shares drop

100% Center coverage: 1 sources

(Reuters) -Drug developer PepGen said on Wednesday it will discontinue development of its experimental therapy for Duchenne muscular dystrophy (DMD) after it failed to boost production of a protein in a mid-stage study. Shares of the company were down 9.5% at $1.43 in extended trading. The therapy PGN-EDO51 did not achieve target levels of dystrophin production. Dystrophin is a protein whose absence leads to muscle weakening in patients with DMD…See the Story

Satellos’ DMD treatment shows efficacy signals in adult patients

Satellos said that following the Phase I data, it will be advancing its DMD small molecule to a Phase II trial.The post Satellos’ DMD treatment shows efficacy signals in adult patients appeared first on Clinical Trials Arena.Irvine, California · Irvine See the Story

News from CureDuchenne